A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.
Rao VK, Webster S, Šedivá A, Plebani A, Schuetz C, Shcherbina A, Conlon N, Coulter T, Dalm VA, Trizzino A, Zharankova Y, Kulm E, Körholz J, Lougaris V, Rodina Y, Radford K, Bradt J, Kucher K, Relan A, Holland SM, Lenardo MJ, Uzel G.
Rao VK, et al. Among authors: shcherbina a.
Blood. 2023 Mar 2;141(9):971-983. doi: 10.1182/blood.2022018546.
Blood. 2023.
PMID: 36399712
Free PMC article.
Clinical Trial.